img

Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Radioimmunotherapy market size was US$ 1042.83 million in 2022 and is forecast to a readjusted size of US$ 4479 million by 2029 with a CAGR of 17.43% during the forecast period 2024-2034.
The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, and etc. In 2022, the global top five players hold a share approximately 99.25% in terms of revenue.
The United States Radioimmunotherapy market size was US$ 504.62 million in 2022, while China size was US$ 23.72 million. The proportion of the United States was 48.39% in 2022, while China percentage was 2.27%, and it is predicted that China share will reach 1.44% in 2029, trailing a CAGR of 20.26 % through the analysis period. As for the Europe Radioimmunotherapy landscape, Germany is projected to reach US$ 327 million by 2029.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Radioimmunotherapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Radioimmunotherapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Radioimmunotherapy market. Readers of the report can become informed about current and future trends of the global Radioimmunotherapy market and how they will impact market growth during the forecast period.




By Company


Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
On Pipeline
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Segment by Type
Beta-emitting
Targeted Alpha Therapy


Segment by Application


Non Hodgkin Lymphoma (NHL)
Solid Tumor

By Region
North America
United States
Canada

Asia-Pacific
China
Japan
South Korea
India
Southeast Asia

Europe
Germany
France
U.K.
Italy
Russia

Latin America
Mexico
Brazil

Middle East & Africa
Middle East
Africa



Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Radioimmunotherapy in global and regional level.
Chapter 3Detailed analysis of Radioimmunotherapy companies鈥 competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7Europe by Type, by Application and by country, revenue for each segment.
Chapter 8Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9Latin America by Type, by Application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin, and Business Strategy, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1
1.2.2 Targeted Alpha Therapy 3
1.2.3 Beta-emitting 4
1.3 Market by Application 7
1.3.1 Global Radioimmunotherapy Market Growth by Application: 2018 VS 2022 VS 2029 7
1.3.2 Non Hodgkin Lymphoma (NHL) 9
1.3.3 Solid Tumor 10
1.4 Assumptions and Limitations 12
1.5 Study Objectives 13
1.6 Years Considered 14
2 Market Perspective 15
2.1 Global Radioimmunotherapy Market Size 2018-2029 15
2.2 Radioimmunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029 16
2.3 Global Radioimmunotherapy Market Size by Region (2018-2024) 18
2.4 Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) 20
2.5 Global Top 10 Radioimmunotherapy Countries Ranking by Market Size 21
3 Radioimmunotherapy Competition by Company 23
3.1 Global Radioimmunotherapy Revenue by Players 23
3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2024) 23
3.1.2 Global Radioimmunotherapy Market Share by Players (2018-2024) 24
3.2 Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) 25
3.3 Company Covered: Ranking by Radioimmunotherapy Revenue 25
3.4 Global Radioimmunotherapy Market Concentration Ratio 26
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI) 26
3.4.2 Global Top 5 Companies by Radioimmunotherapy Revenue in 2022 27
3.5 Global Key Players of Radioimmunotherapy Head office and Area Served 27
3.6 Global Key Players of Radioimmunotherapy, Product and Application 28
3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28
3.8 Mergers & Acquisitions, Expansion Plans 29
4 Global Radioimmunotherapy Breakdown Data by Type 30
4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2024) 30
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) 31
5 Global Radioimmunotherapy Breakdown Data by Application 32
5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2024) 32
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) 33
6 North America 34
6.1 North America Radioimmunotherapy Revenue by Company (2021-2024) 34
6.2 North America Radioimmunotherapy Revenue by Type (2018-2029) 35
6.3 North America Radioimmunotherapy Revenue by Application (2018-2029) 36
6.4 North America Radioimmunotherapy Revenue by Country (2018-2029) 37
6.4.1 United States 38
6.4.2 Canada 39
7 Europe 40
7.1 Europe Radioimmunotherapy Revenue by Company (2021-2024) 40
7.2 Europe Radioimmunotherapy Revenue by Type (2018-2029) 41
7.3 Europe Radioimmunotherapy Revenue by Application (2018-2029) 42
7.4 Europe Radioimmunotherapy Revenue by Country (2018-2029) 43
7.4.1 Germany 45
7.4.2 France 45
7.4.3 U.K. 46
7.4.4 Italy 46
7.4.5 Russia 47
8 Asia Pacific 48
8.1 Asia Pacific Radioimmunotherapy Revenue by Company (2021-2024) 48
8.2 Asia Pacific Radioimmunotherapy Revenue by Type (2018-2029) 49
8.3 Asia Pacific Radioimmunotherapy Revenue by Application (2018-2029) 50
8.4 Asia Pacific Radioimmunotherapy Revenue by Region (2018-2029) 51
8.4.1 China 53
8.4.2 Japan 53
8.4.3 South Korea 54
8.4.4 India 54
8.4.5 Southeast Asia 55
9 Latin America 56
9.1 Latin America Radioimmunotherapy Revenue by Company (2021-2024) 56
9.2 Latin America Radioimmunotherapy Revenue by Type (2018-2029) 57
9.3 Latin America Radioimmunotherapy Revenue by Application (2018-2029) 58
9.4 Latin America Radioimmunotherapy Revenue by Country (2018-2029) 58
9.4.1 Mexico 60
9.4.2 Brazil 60
10 Middle East and Africa 61
10.1 Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2024) 61
10.2 Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2029) 62
10.3 Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2029) 63
10.4 Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2029) 63
10.4.1 Middle East 65
10.4.2 Africa 65
11 Company Profiles 66
11.1 Bayer 66
11.1.1 Bayer Company Details 66
11.1.2 Bayer Business Overview 66
11.1.3 Bayer Radioimmunotherapy Products and Services 67
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2024) 68
11.1.5 Bayer Radioimmunotherapy SWOT Analysis 68
11.1.6 Bayer Business Strategy 69
11.2 Novartis 69
11.2.1 Novartis Company Details 70
11.2.2 Novartis Business Overview 70
11.2.3 Novartis Radioimmunotherapy Products and Services 71
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2024) 72
11.2.5 Novartis Radioimmunotherapy SWOT Analysis 72
11.2.6 Novartis Business Strategy 73
11.3 Lantheus 73
11.3.1 Lantheus Company Details 74
11.3.2 Lantheus Business Overview 74
11.3.3 Lantheus Radioimmunotherapy Products and Services 75
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2024) 75
11.3.5 Lantheus Radioimmunotherapy SWOT Analysis 76
11.3.6 Lantheus Business Strategy 77
11.4 Aurobindo Pharma 77
11.4.1 Aurobindo Pharma Company Details 78
11.4.2 Aurobindo Pharma Business Overview 78
11.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 79
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024) 79
11.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80
11.4.6 Aurobindo Pharma Business Strategy 81
11.5 Mundipharma 81
11.5.1 Mundipharma Company Details 81
11.5.2 Mundipharma Business Overview 82
11.5.3 Mundipharma Radioimmunotherapy Products and Services 83
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2024) 83
11.5.5 Mundipharma Business Strategy 84
11.6 China Isotope & Radiation 84
11.6.1 China Isotope & Radiation Company Details 84
11.6.2 China Isotope & Radiation Business Overview 85
11.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 85
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024) 86
11.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86
11.6.6 China Isotope & Radiation Business Strategy 87
11.7 Curium Pharmaceuticals 88
11.7.1 Curium Pharmaceuticals Company Details 88
11.7.2 Curium Pharmaceuticals Business Overview 88
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 89
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) 89
11.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90
11.7.6 Curium Pharmaceuticals Business Strategy 91
11.8 Gilead Sciences 91
11.8.1 Gilead Sciences Company Details 92
11.8.2 Gilead Sciences Business Overview 92
11.8.3 Gilead Sciences Radioimmunotherapy Products and Services 93
11.8.4 Gilead Sciences Business Strategy 93
11.9 Clarity Pharmaceuticals 94
11.9.1 Clarity Pharmaceuticals Company Details 94
11.9.2 Clarity Pharmaceuticals Business Overview 94
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95
11.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95
11.9.5 Clarity Pharmaceuticals Business Strategy 96
11.10 Curasight 96
11.10.1 Curasight Company Details 96
11.10.2 Curasight Business Overview 97
11.10.3 Curasight Radioimmunotherapy Products and Services 97
11.10.4 Curasight Radioimmunotherapy SWOT Analysis 98
11.10.5 Curasight Business Strategy 98
11.11 Nordic Nanovector 99
11.11.1 Nordic Nanovector Company Details 99
11.11.2 Nordic Nanovector Business Overview 100
11.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 100
11.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 100
11.11.5 Nordic Nanovector Business Strategy 101
11.12 Philogen 102
11.12.1 Philogen Company Details 102
11.12.2 Philogen Business Overview 102
11.12.3 Philogen Radioimmunotherapy Products and Services 103
11.12.4 Philogen Radioimmunotherapy SWOT Analysis 103
11.12.5 Philogen Business Strategy 104
11.13 RadioMedix 104
11.13.1 RadioMedix Company Details 104
11.13.2 RadioMedix Business Overview 105
11.13.3 RadioMedix Radioimmunotherapy Products and Services 105
11.13.4 RadioMedix Business Strategy 105
11.14 Telix Pharmaceuticals 106
11.14.1 Telix Pharmaceuticals Company Details 106
11.14.2 Telix Pharmaceuticals Business Overview 107
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 107
11.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108
11.14.5 Telix Pharmaceuticals Business Strategy 108
11.15 Orano Med 109
11.15.1 Orano Med Company Details 109
11.15.2 Orano Med Business Overview 110
11.15.3 Orano Med Radioimmunotherapy Products and Services 110
11.15.4 Orano Med Radioimmunotherapy SWOT Analysis 110
11.15.5 Orano Med Business Strategy 111
11.16 Actinium Pharmaceuticals 111
11.16.1 Actinium Pharmaceuticals Company Details 111
11.16.2 Actinium Pharmaceuticals Business Overview 112
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112
11.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113
11.16.5 Actinium Pharmaceuticals Business Strategy 113
11.17 Y-mAbs Therapeutics 114
11.17.1 Y-mAbs Therapeutics Company Details 114
11.17.2 Y-mAbs Therapeutics Business Overview 114
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115
11.17.4 Y-mAbs Therapeutics Business Strategy 116
11.18 Fusion Pharmaceuticals 116
11.18.1 Fusion Pharmaceuticals Company Details 116
11.18.2 Fusion Pharmaceuticals Business Overview 117
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117
11.18.4 Fusion Pharmaceuticals Business Strategy 118
12 Radioimmunotherapy Market Dynamics 120
12.1 Radioimmunotherapy Industry Trends 120
12.2 Radioimmunotherapy Market Drivers 121
12.3 Radioimmunotherapy Market Challenges 122
12.4 Radioimmunotherapy Market Restraints 123
13 Research Findings and Conclusion 124
14 Appendix 126
14.1 Research Methodology 126
14.1.1 Methodology/Research Approach 126
14.1.2 Data Source 129
14.2 Author Details 132
14.3 Disclaimer 135

List of Figure

Table 1. Global Radioimmunotherapy Market Size Growth Rate (CAGR) by Type (US$ Million): 2018 VS 2022 VS 2029 1
Table 2. Key Players of Ibritumomab 5
Table 3. Key Players of Apamistamab 5
Table 4. Key Players of Lilotomab 6
Table 5. Key Players of Omburtamab 6
Table 6. Global Radioimmunotherapy Market Size Growth Rate (CAGR) by Application (US$ Million): 2018 VS 2022 VS 2029 7
Table 7. Global Radioimmunotherapy Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029 17
Table 8. Global Radioimmunotherapy Revenue by Region (2018-2024) & (US$ Million) 18
Table 9. Global Radioimmunotherapy Revenue Forecast by Region (2024-2029) & (US$ Million) 20
Table 10. Global Radioimmunotherapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2029, (US$ Million) 21
Table 11. Global Radioimmunotherapy Revenue by Players (2018-2024) & (US$ Million) 23
Table 12. Global Radioimmunotherapy Market Share by Players (2018-2024) 24
Table 13. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2022) 25
Table 14. Ranking of Global Top Radioimmunotherapy Companies by Revenue (US$ Million) in 2022 25
Table 15. Global 5 Largest Players Market Share by Radioimmunotherapy Revenue (CR5 and HHI) & (2018-2024) 26
Table 16. Global Key Players of Radioimmunotherapy, Headquarters and Area Served 27
Table 17. Global Key Players of Radioimmunotherapy, Product and Application 28
Table 18. Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28
Table 19. Mergers & Acquisitions, Expansion Plans 29
Table 20. Global Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million) 30
Table 21. Global Radioimmunotherapy Revenue Market Share by Type (2018-2024) 30
Table 22. Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million) 31
Table 23. Global Radioimmunotherapy Revenue Market Share by Type (2024-2029) 31
Table 24. Global Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million) 32
Table 25. Global Radioimmunotherapy Revenue Market Share by Application (2018-2024) 32
Table 26. Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million) 33
Table 27. Global Radioimmunotherapy Revenue Market Share by Application (2024-2029) 33
Table 28. North America Radioimmunotherapy Revenue by Company (2021-2024) & (US$ Million) 34
Table 29. North America Radioimmunotherapy Revenue by Type (2018-2024) & (US$ Million) 35
Table 30. North America Radioimmunotherapy Revenue by Type (2024-2029) & (US$ Million) 35
Table 31. North America Radioimmunotherapy Revenue by Application (2018-2024) & (US$ Million) 36
Table 32. North America Radioimmunotherapy Revenue by Application (2024-2029) & (US$ Million) 36
Table 33. North America Radioimmunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 37
Table 34. North America Radioimmunotherapy Revenue by Country (2018-2024) & (US$ Million) 37
Table 35. North America Radioimmunotherapy Revenue by Country (2024-2029) & (US$ Million) 37
Table 36. Europe Radioimmunotherapy Revenue by Company (2021-2024) & (US$ Million) 40
Table 37. Europe Radioimmunotherapy Revenue by Type (2018-2024) & (US$ Million) 41
Table 38. Europe Radioimmunotherapy Revenue by Type (2024-2029) & (US$ Million) 41
Table 39. Europe Radioimmunotherapy Revenue by Application (2018-2024) & (US$ Million) 42
Table 40. Europe Radioimmunotherapy Revenue by Application (2024-2029) & (US$ Million) 42
Table 41. Europe Radioimmunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 43
Table 42. Europe Radioimmunotherapy Revenue by Country (2018-2024) & (US$ Million) 43
Table 43. Europe Radioimmunotherapy Revenue by Country (2024-2029) & (US$ Million) 43
Table 44. Asia Pacific Radioimmunotherapy Revenue by Company (2021-2024) & (US$ Million) 48
Table 45. Asia Pacific Radioimmunotherapy Revenue by Type (2018-2024) & (US$ Million) 49
Table 46. Asia Pacific Radioimmunotherapy Revenue by Type (2024-2029) & (US$ Million) 49
Table 47. Asia Pacific Radioimmunotherapy Revenue by Application (2018-2024) & (US$ Million) 50
Table 48. Asia Pacific Radioimmunotherapy Revenue by Application (2024-2029) & (US$ Million) 50
Table 49. Asia-Pacific Radioimmunotherapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029 51
Table 50. Asia Pacific Radioimmunotherapy Revenue by Region (2018-2024) & (US$ Million) 51
Table 51. Asia Pacific Radioimmunotherapy Revenue by Region (2024-2029) & (US$ Million) 51
Table 52. Latin America Radioimmunotherapy Revenue by Company (2021-2024) & (US$ Million) 56
Table 53. Latin America Radioimmunotherapy Revenue by Type (2018-2024) & (US$ Million) 57
Table 54. Latin America Radioimmunotherapy Revenue by Type (2024-2029) & (US$ Million) 57
Table 55. Latin America Radioimmunotherapy Revenue by Application (2018-2024) & (US$ Million) 58
Table 56. Latin America Radioimmunotherapy Revenue by Application (2024-2029) & (US$ Million) 58
Table 57. Latin America Radioimmunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 58
Table 58. Latin America Radioimmunotherapy Revenue by Country (2018-2024) & (US$ Million) 59
Table 59. Latin America Radioimmunotherapy Revenue by Country (2024-2029) & (US$ Million) 59
Table 60. Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2024) & (US$ Million) 61
Table 61. Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2024) & (US$ Million) 62
Table 62. Middle East and Africa Radioimmunotherapy Revenue by Type (2024-2029) & (US$ Million) 62
Table 63. Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2024) & (US$ Million) 63
Table 64. Middle East and Africa Radioimmunotherapy Revenue by Application (2024-2029) & (US$ Million) 63
Table 65. Middle East and Africa Radioimmunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 63
Table 66. Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2024) & (US$ Million) 64
Table 67. Middle East and Africa Radioimmunotherapy Revenue by Country (2024-2029) & (US$ Million) 64
Table 68. Bayer Company Details 66
Table 69. Bayer Business Overview 66
Table 70. Bayer Radioimmunotherapy Products and Services 67
Table 71. Bayer Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 68
Table 72. Bayer Radioimmunotherapy SWOT Analysis 68
Table 73. Bayer Business Strategy 69
Table 74. Novartis Company Details 70
Table 75. Novartis Business Overview 70
Table 76. Novartis Radioimmunotherapy Products and Services 71
Table 77. Novartis Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 72
Table 78. Novartis Radioimmunotherapy SWOT Analysis 72
Table 79. Novartis Business Strategy 73
Table 80. Lantheus Company Details 74
Table 81. Lantheus Business Overview 74
Table 82. Lantheus Radioimmunotherapy Products and Services 75
Table 83. Lantheus Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 75
Table 84. Lantheus Radioimmunotherapy SWOT Analysis 76
Table 85. Lantheus Business Strategy 77
Table 86. Aurobindo Pharma Company Details 78
Table 87. Aurobindo Pharma Business Overview 78
Table 88. Aurobindo Pharma Radioimmunotherapy Products and Services 79
Table 89. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 79
Table 90. Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80
Table 91. Aurobindo Pharma Business Strategy 81
Table 92. Mundipharma Company Details 81
Table 93. Mundipharma Business Overview 82
Table 94. Mundipharma Radioimmunotherapy Products and Services 83
Table 95. Mundipharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 83
Table 96. Mundipharma Business Strategy 84
Table 97. China Isotope & Radiation Company Details 84
Table 98. China Isotope & Radiation Business Overview 85
Table 99. China Isotope & Radiation Radioimmunotherapy Products and Services 85
Table 100. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 86
Table 101. China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86
Table 102. China Isotope & Radiation Business Strategy 87
Table 103. Curium Pharmaceuticals Company Details 88
Table 104. Curium Pharmaceuticals Business Overview 88
Table 105. Curium Pharmaceuticals Radioimmunotherapy Products and Services 89
Table 106. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million) 89
Table 107. Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90
Table 108. Curium Pharmaceuticals Business Strategy 91
Table 109. Gilead Sciences Company Details 92
Table 110. Gilead Sciences Business Overview 92
Table 111. Gilead Sciences Radioimmunotherapy Products and Services 93
Table 112. Gilead Sciences Business Strategy 93
Table 113. Clarity Pharmaceuticals Company Details 94
Table 114. Clarity Pharmaceuticals Business Overview 94
Table 115. Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95
Table 116. Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95
Table 117. Clarity Pharmaceuticals Business Strategy 96
Table 118. Curasight Company Details 96
Table 119. Curasight Business Overview 97
Table 120. Curasight Radioimmunotherapy Products and Services 97
Table 121. Curasight Radioimmunotherapy SWOT Analysis 98
Table 122. Curasight Business Strategy 98
Table 123. Nordic Nanovector Company Details 99
Table 124. Nordic Nanovector Business Overview 100
Table 125. Nordic Nanovector Radioimmunotherapy Products and Services 100
Table 126. Nordic Nanovector Radioimmunotherapy SWOT Analysis 100
Table 127. Nordic Nanovector Business Strategy 101
Table 128. Philogen Company Details 102
Table 129. Philogen Business Overview 102
Table 130. Philogen Radioimmunotherapy Products and Services 103
Table 131. Philogen Radioimmunotherapy SWOT Analysis 103
Table 132. Philogen Business Strategy 104
Table 133. RadioMedix Company Details 104
Table 134. RadioMedix Business Overview 105
Table 135. RadioMedix Radioimmunotherapy Products and Services 105
Table 136. RadioMedix Business Strategy 105
Table 137. Telix Pharmaceuticals Company Details 106
Table 138. Telix Pharmaceuticals Business Overview 107
Table 139. Telix Pharmaceuticals Radioimmunotherapy Products and Services 107
Table 140. Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108
Table 141. Telix Pharmaceuticals Business Strategy 108
Table 142. Orano Med Company Details 109
Table 143. Orano Med Business Overview 110
Table 144. Orano Med Radioimmunotherapy Products and Services 110
Table 145. Orano Med Radioimmunotherapy SWOT Analysis 110
Table 146. Orano Med Business Strategy 111
Table 147. Actinium Pharmaceuticals Company Details 111
Table 148. Actinium Pharmaceuticals Business Overview 112
Table 149. Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112
Table 150. Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113
Table 151. Actinium Pharmaceuticals Business Strategy 113
Table 152. Y-mAbs Therapeutics Company Details 114
Table 153. Y-mAbs Therapeutics Business Overview 114
Table 154. Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115
Table 155. Y-mAbs Therapeutics Business Strategy 116
Table 156. Fusion Pharmaceuticals Company Details 116
Table 157. Fusion Pharmaceuticals Business Overview 117
Table 158. Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117
Table 159. Fusion Pharmaceuticals Business Strategy 118
Table 160. Radioimmunotherapy Market Trends 120
Table 161. Radioimmunotherapy Market Drivers 121
Table 162. Radioimmunotherapy Market Challenges 122
Table 163. Radioimmunotherapy Market Restraints 123
Table 164. Research Programs/Design for This Report 126
Table 165. Key Data Information from Secondary Sources 130
Table 166. Key Data Information from Primary Sources 131
Table 167. QYR Business Unit and Senior & Team Lead Analysts 133



List of Figures

Figure 1. Global Radioimmunotherapy Market Size by Type (US$ Million): 2018-2029 2
Figure 2. Global Radioimmunotherapy Market Share by Type: 2022 2
Figure 3. Global Radioimmunotherapy Market Share by Type: 2029 3
Figure 4. Targeted Alpha Therapy Features 4
Figure 5. Ibritumomab Features 5
Figure 6. Tositumomab Features 7
Figure 7. Global Radioimmunotherapy Market Size by Application (US$ Million): 2018-2029 8
Figure 8. Global Radioimmunotherapy Market Share by Application: 2022 9
Figure 9. Global Radioimmunotherapy Market Share by Application: 2029 9
Figure 10. Non Hodgkin Lymphoma (NHL) 10
Figure 11. Prostate Cancer 11
Figure 12. Radioimmunotherapy Report Years Considered 14
Figure 13. Global Radioimmunotherapy Revenue, (US$ Million), 2018 VS 2024 VS 2029 15
Figure 14. Global Radioimmunotherapy Market Size 2018-2029 (US$ Million) 16
Figure 15. Global Radioimmunotherapy Market Size Market Share by Region: 2022 17
Figure 16. Global Radioimmunotherapy Market Size Market Share by Region: 2029 18
Figure 17. Global Radioimmunotherapy Revenue Market Share by Region in 2018 19
Figure 18. Global Radioimmunotherapy Revenue Market Share by Region in 2024 19
Figure 19. Global Radioimmunotherapy Revenue Market Share Forecast by Region (2024-2029) 20
Figure 20. Global Top 10 Radioimmunotherapy Countries Ranking by Market Size (US$ Million) in 2022 21
Figure 21. Global Radioimmunotherapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2029, (US$ Million) 22
Figure 22. Global Radioimmunotherapy Market Share by Players in 2022 24
Figure 23. The Top 5 Players Market Share by Radioimmunotherapy Revenue in 2022 27
Figure 24. North America Radioimmunotherapy Revenue Market Share by Company in 2022 34
Figure 25. North America Radioimmunotherapy Revenue Market Share by Type (2018-2029) 35
Figure 26. North America Radioimmunotherapy Revenue Market Share by Application (2018-2029) 36
Figure 27. North America Radioimmunotherapy Revenue Share by Country (2018-2029) 38
Figure 28. United States Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 38
Figure 29. Canada Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 39
Figure 30. Europe Radioimmunotherapy Revenue Market Share by Company in 2022 40
Figure 31. Europe Radioimmunotherapy Revenue Market Share by Type (2018-2029) 41
Figure 32. Europe Radioimmunotherapy Revenue Market Share by Application (2018-2029) 42
Figure 33. Europe Radioimmunotherapy Revenue Share by Country (2018-2029) 44
Figure 34. Germany Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 45
Figure 35. France Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 45
Figure 36. U.K. Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 46
Figure 37. Italy Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 46
Figure 38. Russia Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 47
Figure 39. Asia Pacific Radioimmunotherapy Revenue Market Share by Company in 2022 48
Figure 40. Asia Pacific Radioimmunotherapy Revenue Market Share by Type (2018-2029) 49
Figure 41. Asia Pacific Radioimmunotherapy Revenue Market Share by Application (2018-2029) 50
Figure 42. Asia Pacific Radioimmunotherapy Revenue Share by Region (2018-2029) 52
Figure 43. China Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 53
Figure 44. Japan Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 53
Figure 45. South Korea Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 54
Figure 46. India Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 54
Figure 47. Southeast Asia Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 55
Figure 48. Latin America Radioimmunotherapy Revenue Market Share by Company in 2022 56
Figure 49. Latin America Radioimmunotherapy Revenue Market Share by Type (2018-2029) 57
Figure 50. Latin America Radioimmunotherapy Revenue Share by Country (2018-2029) 59
Figure 51. Mexico Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 60
Figure 52. Brazil Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 60
Figure 53. Middle East and Africa Radioimmunotherapy Revenue Market Share by Company in 2022 61
Figure 54. Middle East and Africa Radioimmunotherapy Revenue Market Share by Type (2018-2029) 62
Figure 55. Middle East and Africa Radioimmunotherapy Revenue Share by Country (2018-2029) 64
Figure 56. Middle East Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 65
Figure 57. Africa Radioimmunotherapy Revenue (2018-2029) & (US$ Million) 65
Figure 58. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 68
Figure 59. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 72
Figure 60. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 76
Figure 61. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 80
Figure 62. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 83
Figure 63. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 86
Figure 64. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024) 90
Figure 65. Bottom-up and Top-down Approaches for This Report 128
Figure 66. Data Triangulation 129
Figure 67. Key Executives Interviewed 131

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries